Regulatory Risk Assessment of Pharmaceuticals in the Environment: Current Practice and Future Priorities

被引:6
|
作者
Oldenkamp, Rik [1 ,2 ]
Hamers, Timo [1 ]
Wilkinson, John [3 ]
Slootweg, Jaap [4 ]
Posthuma, Leo [4 ,5 ]
机构
[1] Vrije Univ Amsterdam, Amsterdam Inst Life & Environm, Fac Sci, Amsterdam, Netherlands
[2] Univ Amsterdam, Amsterdam Inst Global Hlth & Dev, Amsterdam, Netherlands
[3] Univ York, Environm & Geog Dept, York, England
[4] RIVM, Ctr Sustainabil Environm & Hlth, Bilthoven, Netherlands
[5] Radboud Univ Nijmegen, Dept Environm Sci, Nijmegen, Netherlands
关键词
Chemical regulation; ecological risk assessment; pharmaceuticals; species sensitivity distributions; PERSONAL CARE PRODUCTS; TRIGGER VALUES; IN-VITRO; MIXTURES;
D O I
10.1002/etc.5535
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
How can data on the occurrence of pharmaceuticals and personal care products (PPCPs) in the environment and the quality of ecosystems exposed to PPCPs be used to determine whether current regulatory risk assessment schemes are effective? This is one of 20 "big questions" concerning PPCPs in the environment posed in a landmark review paper in 2012. Ten years later, we review the developments around this question, focusing on the first P in PPCPs, that is, pharmaceuticals, or more specifically the active ingredients included in them (active pharmaceutical ingredients, APIs). We illustrate how extensive data on both the occurrence of APIs and the ecotoxicological sensitivity of aquatic species to them can be used in a retrospective risk assessment. In the Netherlands, current regulatory risk assessment schemes offer insufficient protection against direct ecotoxicological effects from APIs: the toxic pressure exerted by the 39 APIs included in our study exceeds the policy-related protective threshold of 0.05 (the "95%-protection level") in at least 13% of sampled surface waters. In general, anti-inflammatory and antirheumatic products (e.g., diclofenac, ibuprofen) contributed most to the overall toxic pressure, followed by sex hormones and modulators of the genital system (e.g., ethinylestradiol) and psychoanaleptics (e.g., caffeine). We formulated three open questions for future research. The first relates to improving the availability and accessibility of good-quality ecotoxicity data on pharmaceuticals for the global scientific, regulatory, and general public. The second relates to the adaptation of regulatory risk assessment frameworks for developing regions of the world. The third relates to the integration of effect-based and ecological approaches into regulatory risk assessment practice. Environ Toxicol Chem 2023;00:1-12. (c) 2022 The Authors. Environmental Toxicology and Chemistry published by Wiley Periodicals LLC on behalf of SETAC.
引用
收藏
页码:611 / 622
页数:12
相关论文
共 50 条
  • [1] The Risk Assessment of Pharmaceuticals in the Environment: EU and US Regulatory Approach
    Walter, Shona
    Mitkidis, Katerina
    EUROPEAN JOURNAL OF RISK REGULATION, 2018, 9 (03) : 527 - 547
  • [2] Global Pediatric Anesthesiology: Current Practice and Future Priorities
    Kynes, James Matthew
    Sobey, Jenna H.
    Zeigler, Laura N.
    Crockett, Christy
    McQueen, Kathryn A. Kelly
    INTERNATIONAL ANESTHESIOLOGY CLINICS, 2019, 57 (04) : 84 - 102
  • [3] Environmental risk assessment of six human pharmaceuticals:: Are the current environmental risk assessment procedures sufficient for the protection of the aquatic environment?
    Ferrari, B
    Mons, R
    Vollat, B
    Fraysse, B
    Paxéus, N
    Lo Giudice, R
    Pollio, A
    Garric, J
    ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY, 2004, 23 (05) : 1344 - 1354
  • [4] Preliminary risk assessment database and risk ranking of pharmaceuticals in the environment
    Cooper, Emily R.
    Siewicki, Thomas C.
    Phillips, Karl
    SCIENCE OF THE TOTAL ENVIRONMENT, 2008, 398 (1-3) : 26 - 33
  • [5] Regulatory perspectives on pharmaceuticals in the environment
    Agerstrand, Marlene
    Breitholtz, Magnus
    Hansson, Sven Ove
    Ruden, Christina
    TOXICOLOGY LETTERS, 2012, 211 : S31 - S31
  • [6] Pharmaceuticals in the aquatic environment - a comparison of risk assessment strategies
    Bound, JP
    Voulvoulis, N
    CHEMOSPHERE, 2004, 56 (11) : 1143 - 1155
  • [7] A human health risk assessment of pharmaceuticals in the aquatic environment
    Schulman, LJ
    Sargent, EV
    Naumann, BD
    Faria, EC
    Dolan, DG
    Wargo, JP
    HUMAN AND ECOLOGICAL RISK ASSESSMENT, 2002, 8 (04): : 657 - 680
  • [8] Regulatory assessment of risk to the environment: Radiation
    Dooley, BL
    Colgan, PJ
    Burns, PA
    PROTECTION OF THE ENVIRONMENT FROM IONISING RADIATION: THE DEVELOPMENT AND APPLICATION OF A SYSTEM OF RADIATION PROTECTION FOR THE ENVIRONMENT, 2003, 17 : 203 - 212
  • [9] Regulatory demands on data quality for the environmental risk assessment of pharmaceuticals
    Kuester, A.
    Bachmann, J.
    Brandt, U.
    Ebert, I.
    Hickmann, S.
    Klein-Goedicke, J.
    Maack, G.
    Schmitz, S.
    Thumm, E.
    Rechenberg, B.
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2009, 55 (03) : 276 - 280
  • [10] Pharmaceuticals in the Environment: Regulatory Challenges Ahead
    Conerly, Octavia
    Ohanian, Edward V.
    HUMAN AND ECOLOGICAL RISK ASSESSMENT, 2010, 16 (06): : 1234 - 1241